Bad phosphorylation as a target of inhibition in oncology

被引：65

作者：

Bui, Ngoc-Linh-Chi ^{[1
]}

Pandey, Vijay ^{[2
]}

Zhu, Tao ^{[3
,4
,5
]}

Ma, Lan ^{[2
]}

Basappa ^{[6
]}

Lobie, Peter E. ^{[1
,2
,7
]}

机构：

[1] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore

[2] Tsinghua Univ, Tsinghua Berkeley Shenzhen Inst, Shenzhen, Guangdong, Peoples R China

[3] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei, Anhui, Peoples R China

[4] Univ Sci & Technol China, Sch Life Sci, Hefei, Anhui, Peoples R China

[5] Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Hefei, Anhui, Peoples R China

[6] Univ Mysore, Dept Studies Organ Chem, Lab Chem Biol, Mysore 570006, Karnataka, India

[7] Natl Univ Singapore, Canc Inst, Natl Univ Hlth Syst, Singapore, Singapore

来源：

CANCER LETTERS | 2018年 / 415卷

基金：

新加坡国家研究基金会; 英国医学研究理事会;

关键词：

BAD phosphorylation; Apoptosis; kinase inhibitor; Bcl-2; family; CHRONIC LYMPHOCYTIC-LEUKEMIA; EPIDERMAL-GROWTH-FACTOR; APOPTOTIC PHOSPHO-BAD; KRAS MUTANT LUNG; PROTEIN-KINASE; CELL-DEATH; NAVITOCLAX ABT-263; SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL; 3-KINASE; BREAST-CANCER;

D O I：

10.1016/j.canlet.2017.11.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Bcl-2 agonist of cell death (BAD) is a BH3-only member of the Bcl-2 family which possesses important regulatory function in apoptosis. BAD has also been shown to possess many non-apoptotic functions closely linked to cancer including regulation of glycolysis, autophagy, cell cycle progression and immune system development. Interestingly, BAD can be either pro-apoptotic or pro-survival depending on the phosphorylation state of three specific serine residues (human S75, S99 and S118). Expression of BAD and BAD phosphorylation patterns have been shown to influence tumor initiation and progression and play a predictive role in disease prognosis, drug response and chemosensitivity in various cancers. This review aims to summarize the current evidence on the functional role of BAD phosphorylation in human cancer and evaluate the potential utility of modulating BAD phosphorylation in cancer. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：177 / 186

页数：10

共 160 条

[1]

Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer [J].

Al-Bazz, Yousif O. ;

Underwood, James C. E. ;

Brown, Barry L. ;

Dobson, Pauline R. M. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (04) :694-704

[2]

[Anonymous], 2014, NAT REV DRUG DISCOV, V13, P644

[3]

[Anonymous], 2009, PROG PALLIAT CARE, V17, P131

[4]

Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkh131, 10.1093/nar/gkw1099]

[5]

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives [J].

Asati, Vivek ;

Mahapatra, Debarshi Kar ;

Bharti, Sanjay Kumar .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 109 :314-341

[6]

Protein phosphatase 1α is a Ras-activated Bad phosphatase that regulates interleukin-2 deprivation-induced apoptosis [J].

Ayllón, V ;

Martínez, C ;

García, A ;

Cayla, X ;

Rebollo, A .

EMBO JOURNAL, 2000, 19 (10) :2237-2246

[7]

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL [J].

Balakrishnan, K. ;

Peluso, M. ;

Fu, M. ;

Rosin, N. Y. ;

Burger, J. A. ;

Wierda, W. G. ;

Keating, M. J. ;

Faia, K. ;

O'Brien, S. ;

Kutok, J. L. ;

Gandhi, V. .

LEUKEMIA, 2015, 29 (09) :1811-1822

[8]

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERKI/2 signalling and/or strong P13K signalling in colorectal cancer cell lines [J].

Balmanno, Kathryn ;

Chell, Simon D. ;

Gillings, Annette S. ;

Hayat, Shaista ;

Cook, Simon J. .

INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (10) :2332-2341

[9]

HDGF: a novel jack-of-all-trades in cancer [J].

Bao, Cihang ;

Wang, Jianbo ;

Ma, Wei ;

Wang, Xintong ;

Cheng, Yufeng .

FUTURE ONCOLOGY, 2014, 10 (16) :2675-2685

[10]

BH3 Mimetics: Status of the Field and New Developments [J].

Billard, Christian .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) :1691-1700

← 1 2 3 4 5 6 7 8 9 10 →